UTMDUTAH MEDICAL PRODUCTS INCvs its industry peers
A metric-by-metric comparison of UTAH MEDICAL PRODUCTS INC against SIC 3841 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UTMDThis | $236M#8 | 22.6x#4 | 1.9x#4 | 6.1x#11 | -5.8%#10 | -18.7%#12 | 29.6%#1 | 9.2%#4 | — | — | 20.1%#4 | 1.7%#2 |
| TLSI | $303M#1 | — | 46.3x#14 | 6.7x#13 | 53.4%#2 | -30.6%#14 | -59.7%#12 | -598.9%#14 | — | 5#6 | 2.4%#7 | — |
| TMCI | $294M#2 | — | 4.3x#7 | 1.4x#3 | 1.6%#8 | -5.8%#10 | -25.5%#11 | -87.1%#10 | -47.4%#11 | 2#12 | -37.1%#10 | — |
| EMBC | $294M#3 | 3.5x#1 | — | 0.3x#1 | -3.8%#9 | 21.8%#8 | 22.4%#2 | — | 27.0%#1 | 6#3 | -61.7%#12 | 11.9%#1 |
| ANIK | $281M#4 | — | 2.0x#5 | 2.5x#8 | -5.9%#11 | 80.4%#3 | -9.8%#8 | -8.0%#5 | -8.8%#5 | 4#9 | 134.6%#1 | — |
| INFU | $248M#5 | 31.1x#5 | 4.2x#6 | 1.7x#5 | 6.4%#7 | 182.6%#2 | 8.3%#5 | 11.2%#3 | 9.5%#4 | 9#1 | — | — |
| OSUR | $241M#6 | — | 0.8x#1 | 2.1x#6 | -38.1%#14 | -252.5%#16 | -62.6%#13 | -21.6%#9 | -43.8%#9 | — | 5.9%#5 | — |
| IDXG | $240M#7 | 9.9x#2 | 10.3x#10 | 6.2x#12 | -17.5%#13 | 267.2%#1 | 10.5%#4 | 105.8%#1 | 14.2%#3 | 5#6 | — | — |
| STIM | $227M#9 | — | 12.7x#12 | 1.5x#4 | 99.2%#1 | 10.8%#9 | -21.1%#10 | -218.5%#12 | -43.9%#10 | 3#10 | 2.8%#6 | — |
| PDEX | $222M#10 | 16.8x#3 | 4.7x#8 | 2.9x#9 | 16.5%#4 | 52.2%#7 | 16.8%#3 | 28.7%#2 | 17.3%#2 | 7#2 | 102.2%#2 | — |
| LUCD | $159M#11 | — | 14.5x#13 | 33.7x#14 | 8.3%#6 | -27.4%#13 | -1054.8%#14 | -530.9%#13 | — | 3#10 | -27.4%#9 | — |
| KRMD | $149M#12 | — | 8.2x#9 | 3.6x#10 | 22.2%#3 | 56.5%#5 | -7.2%#7 | -14.6%#6 | -29.4%#8 | 6#3 | -20.2%#8 | — |
| APYX | $128M#13 | — | 12.0x#11 | 2.4x#7 | 9.9%#5 | 52.2%#6 | -12.2%#9 | -105.1%#11 | -23.6%#7 | 6#3 | 35.7%#3 | — |
| MBOT | $96M#14 | — | 1.4x#2 | 821.7x#15 | -88.5%#15 | -14.8%#11 | -12613.0%#15 | -19.1%#8 | -22.4%#6 | 5#6 | -53.7%#11 | — |
| GUTS | $94M#15 | — | — | — | -100.0%#16 | -105.2%#15 | — | — | — | — | — | — |
| SKIN | $89M#16 | — | 1.6x#3 | 0.3x#2 | -10.0%#12 | 67.4%#4 | -6.9%#6 | -17.1%#7 | — | — | -70.9%#13 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 3841). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice